|Bid||13.16 x 1300|
|Ask||13.15 x 1400|
|Day's Range||12.27 - 13.22|
|52 Week Range||7.49 - 23.88|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Oct 14, 1999|
|1y Target Est||N/A|
Shares of Rite Aid Corp. were up 0.1% in after-hours trading on Tuesday after the drugstore chain confirmed that it will continue to offer no-charge COVID-19 testing in December. Rite Aid had announced Tuesday morning that it would begin charging $115 for symptomatic and asymptomatic diagnostic testing starting Dec. 1. The company currently does not charge people who come in for COVID-19 testing at its 301 testing sites. The Department of Health and Human Services said Rite Aid had notified HHS on Nov. 21 that it had conducted more tests than allocated in their contract, and that HHS had requested more funding for Rite Aid in response, according to a statement from Mia Heck, director of external affairs in the office of the assistant secretary for health. A Rite Aid spokesperson declined to comment beyond the news announcement. Rite Aid also on Tuesday announced plans to lower the age requirement for a COVID-19 test to 13 years old from 18 and said it plans to add 1,000 drive-through testing locations. All of the major drugstore chains in the U.S. including CVS Health Corp. and Walgreens Boots Alliance Inc. are offering coronavirus tests. Rite Aid's stock is down 28% so far this year, while the S&P 500 has gained 10.7%.
On Dec. 1 free covid testing at Rite Aid drugstores will be replaced with a $115-per-test program for individuals over age 13.
Rite Aid Corp said on Tuesday it will continue with its no-charge COVID-19 tests in partnership with the U.S. Department of Health and Human Services. The retailer said its no-charge tests that were so far only available to those aged 18 or above will now be extended to 13-year-olds and above, regardless of whether an individual is symptomatic or asymptomatic. Rite Aid operates 301 testing sites across 15 states.